Undervalued Stocks Based on Artificial Intelligence: Returns up to 17.83% in 3 Days

Undervalued Stocks

The Fundamental Package includes our algorithmic forecasts for undervalued stocks screened by fundamental criteria. Our algorithms help you find best opportunities for both long and short positions for the stocks within each fundamental screen. The stocks are selected according to five basic valuation categories:

  • P/E (price to earnings ratio)
  • PEG (price/earnings to growth ratio)
  • price-to-book ratio
  • price-to-sales ratio
  • short ratio

fundamentals
Package Name: Fundamental – Low P/E Stocks
Recommended Positions: Long
Forecast Length: 3 Days (4/21/21 – 4/24/21)
I Know First Average: 5.48%
Undervalued Stocks
Undervalued Stocks chart

10 out of 10 stock prices in this forecast for the Fundamental – Low P/E Stocks Package moved as predicted by the algorithm. The highest trade return came from CLDX, at 17.83%. DXF and MTG saw outstanding returns of 10.95% and 5.81%. The overall average return in this Fundamental – Low P/E Stocks package was 5.48%, providing investors with a 4.39% premium over the S&P 500’s return of 1.09% during the same period.

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. The Company’s pipeline also includes CDX-0158 and CDX-3379.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.